MAY 08, 2020 7:31 AM PDT

Cholesterol Drugs May Boost Healthy Gut Bacteria in Obese People

WRITTEN BY: Annie Lennon

While statins have long been known for their efficacy in treating high cholesterol, until recently, there was no evidence on its benefits for the microbiome. Now though, tesearchers have found that obese people who take cholesterol-lowering statin drugs may be more likely to have healthier gut bacteria than those who don’t.

For their study, researchers from the Flanders Institute for Biotechnology in Belgium used data from the European Union study called MetaCardis to explore the link between cardiovascular disease and gut bacteria. The research project is known for having microbiome data from over 2,000 individuals from Europe across 1,400 variables including medication and body-mass index. 

From the 888 samples studied, they found that those with higher levels of Bacteroides 2 (Bact2) enterotype (a certain microbiome configuration) tended to have a higher body-mass index and a higher liklihood of being obese. This is particularly noteworthy as the Bact2 enterotype is associated with inflammation. Previous studies have shown that while 75% of people with inflammatory bowel disease have the enterotype, just 15% of those without it have the condition. 

The researchers also found that the pattern of enterotypes in obese people taking statins significnatly differed from those who do not take the drug. While just 5.9% of those taking statins had the Bact2 entereotype, 17.7% of those not taking the drug had the Pact 2 microbiome configuration. These results were repeated when analyzing data from the Flemish Gut Flora Project. 

The authors of the study caution that although their findings open an interesting avenue for further research, they should not be taken conclusively. When calculating their results, lifestyle and socioeconomic factors for example were not taken into account. More than this, due to the lack of ethnic diversity in their samples, these results may not apply for different ethnic groups. 

 

Sources: Forbes, Nature

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 20, 2022
Immunology
Rare Soil Microbe Shows Promise as New Antibiotic
APR 20, 2022
Rare Soil Microbe Shows Promise as New Antibiotic
  Antibiotic resistance has increased the demand for new antibiotic treatments. Now, researchers have found that a ...
APR 21, 2022
Drug Discovery & Development
No Link Between Antidepressants and Improved Quality of Life
APR 21, 2022
No Link Between Antidepressants and Improved Quality of Life
Those who use antidepressant medications have a similar health-related quality of life to people who are depressed and w ...
MAY 20, 2022
Drug Discovery & Development
Drug Shows Promise in treating Spinal Cord Injury
MAY 20, 2022
Drug Shows Promise in treating Spinal Cord Injury
A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord compression injury. The correspond ...
MAY 25, 2022
Neuroscience
The Connection Between Bizarre Dreams and Deeper Learning
MAY 25, 2022
The Connection Between Bizarre Dreams and Deeper Learning
A study published in eLife found that wakefulness, non-REM, and REM sleep have complementary functions for learning. Uni ...
JUN 24, 2022
Cannabis Sciences
Decrease in Youth Substance Use During the Pandemic
JUN 24, 2022
Decrease in Youth Substance Use During the Pandemic
A review published in Child and Family Disaster Psychiatry found that youth substance use declined during the COVID-19 p ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
Loading Comments...